Get the Stockscreener App
2.14
0.47%
0.01
After Hours:
2.17
0.03
+1.40%
Nkarta Inc stock is traded at $2.14, with a volume of 556.26K.
It is up +0.47% in the last 24 hours and down -18.32% over the past month.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.
See More
Previous Close:
$2.13
Open:
$2.13
24h Volume:
556.26K
Relative Volume:
0.74
Market Cap:
$152.00M
Revenue:
-
Net Income/Loss:
$-102.61M
P/E Ratio:
-1.5406
EPS:
-1.3891
Net Cash Flow:
$-93.55M
1W Performance:
-1.38%
1M Performance:
-18.32%
6M Performance:
+4.90%
1Y Performance:
+56.20%
1-Day Range:
$2.09
$2.295
1-Week Range:
$2.04
$2.295
52-Week Range:
$1.42
$2.81
Nkarta Inc Stock (NKTX) Company Profile
Name
Nkarta Inc
Sector
Industry
Phone
(925) 407-1049
Address
1150 VETERANS BOULEVARD, SOUTH SAN FRANCISCO
Compare NKTX vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NKTX
Nkarta Inc
|
2.14 | 151.29M | 0 | -102.61M | -93.55M | -1.3891 |
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.73 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.83 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.60 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Nkarta Inc Stock (NKTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-15-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-09-24 | Initiated | Rodman & Renshaw | Buy |
| Aug-14-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-22-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-10-22 | Initiated | Canaccord Genuity | Buy |
| Jul-28-22 | Initiated | Needham | Buy |
| Jul-18-22 | Initiated | SVB Leerink | Outperform |
| Mar-11-22 | Initiated | Raymond James | Outperform |
| Mar-08-22 | Initiated | H.C. Wainwright | Buy |
| Jan-06-22 | Initiated | William Blair | Outperform |
| Nov-18-21 | Initiated | SMBC Nikko | Outperform |
| Jul-16-21 | Initiated | Oppenheimer | Outperform |
| Aug-04-20 | Initiated | Cowen | Outperform |
| Aug-04-20 | Initiated | Evercore ISI | Outperform |
| Aug-04-20 | Initiated | Mizuho | Buy |
| Aug-04-20 | Initiated | Stifel | Buy |
View All
Nkarta Inc Stock (NKTX) Latest News
Stifel reiterates Nkarta stock rating on trial enrollment progress - Investing.com
Nkarta Launches $100 Million At-the-Market Stock Offering - TipRanks
Nkarta launches $100M at-the-market equity program with Stifel - TradingView
Nkarta, Inc. 2025 Annual Report: Advancing Allogeneic CAR NK-Cell Therapies for Cancer and Autoimmune Diseases - Minichart
Nkarta Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Aug Momentum: Should value investors consider Nkarta Inc2026 Institutional & Real-Time Volume Triggers - baoquankhu1.vn
Nkarta (NASDAQ: NKTX) launches $100M at-the-market stock sale plan - Stock Titan
Nkarta Files $350 Million Mixed Shelf - marketscreener.com
Nkarta (NASDAQ: NKTX) launches $100M at-the-market program via $350M shelf - Stock Titan
Nkarta (NASDAQ:NKTX) Releases Quarterly Earnings Results, Misses Expectations By $0.05 EPS - MarketBeat
Nkarta 2025 10-K: Net loss $104.1M, EPS $(1.41) - TradingView
[10-K] Nkarta, Inc. Files Annual R... - Stock Titan
Nkarta (NASDAQ: NKTX) reports 2025 loss and extends cash runway to 2029 - Stock Titan
Nkarta pushes autoimmune cell therapy to higher dose, cash lasts to 2029 - Stock Titan
If You Invested $1,000 in Nkarta, Inc. (NKTX) - Stock Titan
Nkarta (NKTX) to Release Earnings on Tuesday - MarketBeat
Trend Report: Is Nkarta Inc stock a buy or sell2026 Levels & Reliable Intraday Trade Plans - baoquankhu1.vn
Nkarta Inc expected to post a loss of 32 cents a shareEarnings Preview - TradingView
NKTX Q4'25 Earnings: EPS estimate is (0.31) USD - TradingView
Trading Action: Will Nkarta Inc face regulatory challenges2026 Pullback Review & Weekly Setup with High ROI Potential - baoquankhu1.vn
Street Watch: Will Nkarta Inc stock go up in YEAR2026 Volatility Report & Fast Moving Stock Watchlists - baoquankhu1.vn
Nkarta, Inc. (NASDAQ:NKTX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Sectors Review: Is Nkarta Inc stock showing strong momentumMarket Movers & Verified Swing Trading Watchlists - baoquankhu1.vn
Aug Big Picture: How do insiders feel about Nkarta Inc2026 Earnings Impact & High Return Trade Guides - baoquankhu1.vn
Risk On: How sensitive is Nkarta Inc to inflation2025 Earnings Impact & Capital Efficient Trade Techniques - baoquankhu1.vn
NKTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Nkarta to Participate in March Investor Conferences - Yahoo Finance
Profit Review: Does Nkarta Inc have declining or rising EPSWeekly Trade Summary & Reliable Momentum Entry Alerts - baoquankhu1.vn
NKTXNkarta, Inc. Latest Stock News & Market Updates - Stock Titan
Why analysts upgrade Nkarta Inc. stockJuly 2025 Fed Impact & Capital Protection Trade Alerts - mfd.ru
Tang Capital discloses 2.1% Nkarta (NKTX) ownership in Schedule 13G/A - Stock Titan
Death Cross: Will Nkarta Inc stock benefit from M AJuly 2025 Chart Watch & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
How buybacks impact Nkarta Inc. stock valueShort Setup & Weekly Sector Rotation Insights - mfd.ru
Nkarta, Inc. (NASDAQ:NKTX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Is Nkarta Inc. stock dividend yield sustainable2025 Biggest Moves & Safe Entry Zone Identification - mfd.ru
What is Nkarta Inc.’s book value per shareDividend Hike & Low Drawdown Trading Techniques - mfd.ru
What dividend growth rate does Nkarta Inc offer2025 Geopolitical Influence & Fast Moving Stock Watchlists - baoquankhu1.vn
Nkarta (NASDAQ:NKTX) Stock Price Down 1.5%What's Next? - MarketBeat
How sensitive is Nkarta Inc. to inflation2025 Risk Factors & Verified Momentum Stock Alerts - mfd.ru
What dividend growth rate does Nkarta Inc. offer2025 Year in Review & Consistent Growth Equity Picks - mfd.ru
Sentiment Review: Can Nkarta Inc be the next market leaderWeekly Investment Summary & Reliable Price Breakout Signals - baoquankhu1.vn
Aug Macro: What is the earnings history of Workiva IncDividend Hike & Fast Moving Stock Trade Plans - baoquankhu1.vn
Nkarta Insiders Make Handsome Sum Selling Stock At US$2.06 Per Share - simplywall.st
Nkarta, Inc. (NASDAQ:NKTX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Nkarta, Inc. (NASDAQ:NKTX) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Nkarta CEO Hastings sells $53,915 in NKTX stock By Investing.com - Investing.com South Africa
Insider Selling: Nkarta (NASDAQ:NKTX) CEO Sells 26,046 Shares of Stock - MarketBeat
Insider Selling: Nkarta (NASDAQ:NKTX) President Sells 5,649 Shares of Stock - MarketBeat
Nkarta (NKTX) president Nadir sells $11,693 in shares - Investing.com
Nkarta CEO Hastings sells $53,915 in NKTX stock - Investing.com
Growth Value: Is Valens Semiconductor Ltd forming a bullish divergenceMarket Movement Recap & Capital Efficiency Focused Ideas - baoquankhu1.vn
Nkarta Inc Stock (NKTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.04%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):